PT1359905E - Uso de antagonistas de mglur5 para o tratamento de estados pruriginosos - Google Patents

Uso de antagonistas de mglur5 para o tratamento de estados pruriginosos Download PDF

Info

Publication number
PT1359905E
PT1359905E PT02711840T PT02711840T PT1359905E PT 1359905 E PT1359905 E PT 1359905E PT 02711840 T PT02711840 T PT 02711840T PT 02711840 T PT02711840 T PT 02711840T PT 1359905 E PT1359905 E PT 1359905E
Authority
PT
Portugal
Prior art keywords
alkyl
hydrogen
alkoxy
hydroxy
carboxyl
Prior art date
Application number
PT02711840T
Other languages
English (en)
Portuguese (pt)
Inventor
Josef Gottfried Meingassner
Fabrizio Gasparini
Laszlo Urban
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT1359905E publication Critical patent/PT1359905E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PT02711840T 2001-02-07 2002-02-06 Uso de antagonistas de mglur5 para o tratamento de estados pruriginosos PT1359905E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0103045.1A GB0103045D0 (en) 2001-02-07 2001-02-07 Organic Compounds

Publications (1)

Publication Number Publication Date
PT1359905E true PT1359905E (pt) 2006-11-30

Family

ID=9908300

Family Applications (1)

Application Number Title Priority Date Filing Date
PT02711840T PT1359905E (pt) 2001-02-07 2002-02-06 Uso de antagonistas de mglur5 para o tratamento de estados pruriginosos

Country Status (13)

Country Link
US (2) US20040106582A1 (cg-RX-API-DMAC7.html)
EP (1) EP1359905B1 (cg-RX-API-DMAC7.html)
JP (2) JP2004517947A (cg-RX-API-DMAC7.html)
CN (1) CN1253151C (cg-RX-API-DMAC7.html)
AT (1) ATE333869T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002231777A1 (cg-RX-API-DMAC7.html)
BR (1) BR0206917A (cg-RX-API-DMAC7.html)
CA (1) CA2433409C (cg-RX-API-DMAC7.html)
DE (1) DE60213365T2 (cg-RX-API-DMAC7.html)
ES (1) ES2271229T3 (cg-RX-API-DMAC7.html)
GB (1) GB0103045D0 (cg-RX-API-DMAC7.html)
PT (1) PT1359905E (cg-RX-API-DMAC7.html)
WO (1) WO2002062323A2 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0128996D0 (en) * 2001-12-04 2002-01-23 Novartis Ag Organic compounds
GB0322612D0 (en) * 2003-09-26 2003-10-29 Novartis Ag Organic compounds
WO2005044266A1 (en) * 2003-10-31 2005-05-19 Astrazeneca Ab Alkynes i
JP2007509935A (ja) * 2003-10-31 2007-04-19 アストラゼネカ アクチボラグ アルキンズii
WO2005044265A1 (en) * 2003-10-31 2005-05-19 Astrazeneca Ab Alkynes iii
GB0503646D0 (en) * 2005-02-22 2005-03-30 Novartis Ag Organic compounds
GB0508319D0 (en) 2005-04-25 2005-06-01 Novartis Ag Organic compounds
JPWO2014034898A1 (ja) 2012-08-30 2016-08-08 日本新薬株式会社 ピリジン誘導体及び医薬
AU2016273751B2 (en) * 2015-06-03 2020-04-02 F. Hoffmann-La Roche Ag Ethynyl derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013744B1 (en) * 1989-12-29 1994-09-20 Allegran Inc Acetylenes disubstituted with a pyridinyl group and a substituted phenyl group having retinoid like activity
FR2719044B1 (fr) * 1994-04-26 1996-05-31 Cird Galderma Nouveaux composés bi-aromatiques acétylénés à groupement adamantyle, compositions pharmaceutiques et cosmétiques les contenant et utilisations.
US5498795A (en) * 1994-12-29 1996-03-12 Allergan, Inc. Acetylenes disubstituted with hydroxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
US5534641A (en) * 1994-12-29 1996-07-09 Allergan Acetylenes disubstituted with 2-tetrahydropyranoxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
US6774138B2 (en) * 1999-08-31 2004-08-10 Merck & Co., Inc. Thiazolyl(pyridyl)ethyne compounds

Also Published As

Publication number Publication date
DE60213365T2 (de) 2007-08-09
JP2004517947A (ja) 2004-06-17
ES2271229T3 (es) 2007-04-16
ATE333869T1 (de) 2006-08-15
CA2433409C (en) 2010-04-20
EP1359905B1 (en) 2006-07-26
CN1253151C (zh) 2006-04-26
US20040106582A1 (en) 2004-06-03
JP2012131829A (ja) 2012-07-12
CA2433409A1 (en) 2002-08-15
DE60213365D1 (de) 2006-09-07
US20070265279A1 (en) 2007-11-15
WO2002062323A3 (en) 2003-03-20
BR0206917A (pt) 2004-02-03
EP1359905A2 (en) 2003-11-12
AU2002231777A1 (en) 2002-08-19
GB0103045D0 (en) 2001-03-21
CN1535143A (zh) 2004-10-06
WO2002062323A2 (en) 2002-08-15

Similar Documents

Publication Publication Date Title
CA2450777C (en) Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia
AU765644B2 (en) mGluR5 antagonists for the treatment of pain and anxiety
EP1059100A2 (en) Combinations of CRF antagonists and renin-angiotensin system inhibitors
JP2012131829A (ja) そう痒状態の処置のためのmglur5アンタゴニストの使用
EP2786750B2 (en) Agent for reducing adverse side effects of kinase inhibitor
TW202023563A (zh) 新穎喹唑啉egfr抑制劑
JP3832229B2 (ja) フェニルエテンスルホンアミド誘導体含有医薬
EP4426294A2 (en) Compositions and treatments with nirogacestat
ES2649492T3 (es) (S)-pirlindol o sus sales farmacéuticamente aceptables para uso en medicina
JP2026048781A (ja) インドール化合物を用いた疼痛又は間質性膀胱炎の治療方法
US20010056084A1 (en) MGluR5 antagonists for the treatment of pain and anxiety
US20140221385A1 (en) Combinations of serotonin receptor agonists for treatment of movement disorders
KR20080016735A (ko) 헤르페스 바이러스 유래 동통 치료제
JPWO2003068263A1 (ja) 高血圧症治療薬
HK1036758B (en) Antihypertensive combination of valsartan and calcium channel blocker